she injects the medication to herself to get better
Cimzia

Content prepared by Direct Doctor Supply’s Editorial team.


Last Updated On September 21, 2026

How Does Cimzia Work? – The Mechanism of Action Behind Cimzia

Feb 24, 2025

Biologic therapies have transformed modern medicine, offering targeted treatments for chronic diseases that were once challenging to manage. Unlike traditional medications, these advanced therapies use living cells to regulate immune system activity, helping to reduce inflammation at its source.

Cimzia (certolizumab pegol) is a biologic medication designed to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease. By blocking specific inflammatory pathways, Cimzia helps alleviate symptoms and slow disease progression, providing long-term relief for patients.

In this article, we will explore how Cimzia works, detailing how it interacts with the immune system to control inflammation and improve patient outcomes.

Key Takeaways

  • Cimzia (certolizumab pegol) is a pegylated TNF-α inhibitor that reduces chronic inflammation in autoimmune diseases by selectively neutralizing TNF-α, a key driver of inflammatory responses.
  • Its unique molecular structure enhances efficacy and safety, lowering the risk of immunogenicity compared to other TNF inhibitors.
  • Pegylation extends Cimzia’s half-life, ensuring longer-lasting therapeutic effects and allowing for less frequent dosing while maintaining stable drug levels.
  • Unlike other TNF inhibitors, Cimzia lacks an Fc region, minimizing placental transfer and making it a safer option during pregnancy.
  • Its mechanism of action directly influences dosing regimens and its side effect profile, providing a personalized approach to managing chronic inflammatory conditions.
Consult our sales team

If you’re interested in this product.

Book a Meeting

About: Trusted by over 2,000+ global clients since 2014, Direct Doctor Supply has become a leading supplier of cosmetic, skincare, and orthopedic products for medical and aesthetic professionals. Direct Doctor Supply offers a wide range of authentic brand-name products at competitive wholesale prices, sourced from around the world.

How Cimzia Works Against TNF-α to Reduce Inflammation

Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine that plays a central role in immune regulation and the progression of autoimmune diseases. Excess TNF-α drives chronic inflammation, contributing to conditions like rheumatoid arthritis (RA) and Crohn’s disease.

painful stomach

Many patients ask, “How does Cimzia work?” It selectively binds to soluble and membrane-bound TNF-α, preventing its interaction with receptors and disrupting the inflammatory cascade. This targeted inhibition reduces pro-inflammatory activity and helps manage inflammation associated with certain chronic conditions. Patients and healthcare providers looking to order Cimzia online can explore reliable sourcing options through Direct Doctor Supply.

By neutralizing TNF-α, Cimzia slows disease progression, helping to preserve joint health in RA and promote mucosal healing in Crohn’s disease.[1] Cimzia may be prescribed to manage systemic inflammation associated with rheumatoid arthritis or psoriatic arthritis, whereas Orthovisc is designed to help relieve knee osteoarthritis pain through viscosupplementation. Although Cimzia is no longer available from Direct Doctor Supply, practitioners, clinics, and consumers can explore our available products and order Orthovisc online.

What Makes Cimzia Different from Other TNF Inhibitors?

Reviews from previous patients highlight Cimzia’s unique advantages among TNF inhibitors, including its specialized formulation, extended dosing flexibility, and innovative molecular structure. Several factors set Cimzia apart:

  • PEGylation: Enhances drug stability and reduces immune system recognition, lowering the risk of neutralizing antibodies.
  • Flexible Dosing: Provides customizable treatment schedules, allowing injections every two or four weeks to accommodate patient needs.
  • No Fc Region: Lacks the fragment crystallizable (Fc) region found in other TNF inhibitors, reducing immune-related side effects.
  • Pregnancy-Safe Option: Unlike some TNF inhibitors, Cimzia does not actively cross the placenta, making it a preferred choice for pregnant patients.

Clinical Implications of Cimzia’s Mechanism

Cimzia’s unique structure and pharmacokinetics provide key clinical advantages, particularly for specific patient populations. Its minimal placental transfer makes it a preferred tumor necrosis factor (TNF) blocker for pregnant women who need ongoing autoimmune disease management.[2] Unlike other TNF inhibitors containing an Fc region, Cimzia treatment does not actively cross the placenta, allowing for effective disease control while minimizing fetal drug exposure.

checking her shoulder and arm

2026 Study Explores Cimzia’s Safety and Drug Levels During Pregnancy

The 2026 CHERISH study provided further insights into Cimzia’s pharmacokinetics during pregnancy. This peer-reviewed Phase 1B study evaluated certolizumab pegol concentrations and safety in pregnant women with chronic inflammatory diseases. Among the 21 participants enrolled, researchers found that predose Cimzia concentrations were modestly lower during pregnancy than postpartum but remained consistent across trimesters and within the range observed in nonpregnant patients.

The findings support maintaining established Cimzia dosing regimens during pregnancy when clinically appropriate. This research adds to the evidence surrounding Cimzia’s unique pharmacokinetic profile and its potential role in managing inflammatory conditions during pregnancy, although treatment decisions should always be individualized with a healthcare provider.[5]

Additionally, Cimzia’s structural differences contribute to its distinct safety profile. While it shares common TNF inhibitor-associated risks, such as increased susceptibility to infections, its lack of an Fc region reduces the potential for antibody-dependent cellular cytotoxicity. These characteristics are also relevant to discussions of Cimzia reviews, particularly when evaluating its safety, tolerability, and clinical performance. However, individual experiences may vary, and treatment decisions should be based on clinical evidence and a healthcare provider’s guidance.

Another key advantage is Cimzia’s pegylation, which extends its half-life and allows for flexible dosing options:

  • 200 mg every two weeks or
  • 400 mg every four weeks (for certain conditions).

This dosing flexibility improves patient convenience and may increase adherence compared with TNF inhibitors that require more frequent administration. These features make Cimzia a valuable option for long-term autoimmune disease management.

Conclusion

Cimzia is a pegylated tumor necrosis factor (TNF) blocker with a unique molecular structure that sets it apart from other TNF inhibitors. Its pegylation enhances stability and extends its half-life, while the absence of an Fc region minimizes placental transfer, making it a safer option for pregnant patients.

By targeting TNF-α, Cimzia reduces inflammation and slows disease progression in autoimmune conditions like rheumatoid arthritis and Crohn’s disease. With its distinct formulation and long-term efficacy, Cimzia remains a valuable option for patients who need sustained TNF-α inhibition.

FAQs

1. How does Cimzia work compared to other TNF inhibitors? 

Cimzia’s pegylation extends its half-life, and its Fc-free structure makes it unique among TNF inhibitors, reducing placental transfer and immunogenicity.

2. Is Cimzia safe to use during pregnancy? 

Cimzia’s lack of an Fc region minimizes placental transfer, making it a safer TNF inhibitor option during pregnancy.

3. What conditions is Cimzia approved to treat? 

Cimzia is FDA-approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and moderate-to-severe Crohn’s disease.

4. How often do patients need Cimzia injections? 

Depending on the condition being treated, Cimzia is administered every two weeks (200 mg) or once a month (400 mg).

Need help, additional info, or customized deals?

Talk with our sales representative.

Book a Meeting

Citations

[1] Otte, Megan Lynn, Raju Lama Tamang, J. Papapanagiotou, R. Ahmad, P. Dhawan, and A. B. Singh. “Mucosal Healing and Inflammatory Bowel Disease: Therapeutic Implications and New Targets.” World Journal of Gastroenterology, vol. 29, no. 7, 2023, pp. 1157–72. doi:10.3748/wjg.v29.i7.1157.

[2] TNF Inhibitors: Drugs to Block Inflammation. WebMD. https://www.webmd.com/rheumatoid-arthritis/tnf-inhibitor-inflammation. Accessed 18 Sept. 2026.

[3] Diaz-Borjon, A., C. M. Weyand, and J. J. Goronzy. “Treatment of Chronic Inflammatory Diseases with Biologic Agents: Opportunities and Risks for the Elderly.” Experimental Gerontology, vol. 41, no. 12, 2006, pp. 1250–55. doi:10.1016/j.exger.2006.10.010.

[4] Biologics and Inflammatory Bowel Disease (IBD). UChicago Medicine. https://www.uchicagomedicine.org/conditions-services/inflammatory-bowel-disease/treatment/biologics-and-inflammatory-bowel-disease-ibd-crohns-colitis.

[5] Clowse, Megan E. B., et al. “Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label CHERISH Study.” Rheumatology and Therapy, vol. 13, no. 3, June 2026, pp. 813–28. https://doi.org/10.1007/s40744-026-00853-2. PubMed. Accessed 21 Sept. 2026.

Sourcing and accuracy for this article follow our Editorial policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published